Do analysts recommend BON or CASI?

CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, BON or CASI?

Bon Natural Life has higher earnings, but lower revenue than CASI Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.48 -$2M N/A N/A CASI Pharmaceuticals $26.85M 0.10 -$39.26M -$3.01 N/A

Is BON or CASI more profitable?

Bon Natural Life has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets Bon Natural Life N/A N/A N/A CASI Pharmaceuticals -183.93% N/A -131.54%

Do analysts rate CASI or MTEX?

CASI Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe CASI Pharmaceuticals is more favorable than Mannatech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CASI or MTEX?

In the previous week, Mannatech had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 4 mentions for Mannatech and 1 mentions for CASI Pharmaceuticals. Mannatech's average media sentiment score of 0.64 beat CASI Pharmaceuticals' score of 0.00 indicating that Mannatech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mannatech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CASI or AEON?

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher possible upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than AEON Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00

Is CASI or AEON more profitable?

AEON Biopharma has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% AEON Biopharma N/A N/A -994.63%

Do analysts prefer CASI or SYBX?

CASI Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 07/24/2026

Compare

CASI vs. BON, MTEX, AEON, APRE, and SYBX

Should you buy CASI Pharmaceuticals stock or one of its competitors? MarketBeat compares CASI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CASI Pharmaceuticals include Bon Natural Life (BON), Mannatech (MTEX), AEON Biopharma (AEON), Aprea Therapeutics (APRE), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry.

How does CASI Pharmaceuticals compare to Bon Natural Life?

Bon Natural Life (NASDAQ:BON) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Bon Natural Life and Bon Natural Life both had 1 articles in the media. Bon Natural Life's average media sentiment score of 1.91 beat CASI Pharmaceuticals' score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the media.

Company	Overall Sentiment
Bon Natural Life	Very Positive
CASI Pharmaceuticals	Neutral

CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bon Natural Life has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Bon Natural Life has higher earnings, but lower revenue than CASI Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.48	-$2M	N/A	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bon Natural Life has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Bon Natural Life and CASI Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Mannatech?

CASI Pharmaceuticals (NASDAQ:CASI) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Mannatech has higher revenue and earnings than CASI Pharmaceuticals. Mannatech is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

CASI Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe CASI Pharmaceuticals is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mannatech had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 4 mentions for Mannatech and 1 mentions for CASI Pharmaceuticals. Mannatech's average media sentiment score of 0.64 beat CASI Pharmaceuticals' score of 0.00 indicating that Mannatech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mannatech	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mannatech has a net margin of -11.97% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Mannatech	-11.97%	-2,383.34%	-40.24%

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 47.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Summary

CASI Pharmaceuticals beats Mannatech on 9 of the 16 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to AEON Biopharma?

CASI Pharmaceuticals (NASDAQ:CASI) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

AEON Biopharma has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
AEON Biopharma	N/A	N/A	-994.63%

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher possible upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for AEON Biopharma. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
AEON Biopharma	Neutral

AEON Biopharma has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A

Summary

CASI Pharmaceuticals beats AEON Biopharma on 7 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

CASI Pharmaceuticals (NASDAQ:CASI) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aprea Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. Aprea Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A

CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Aprea Therapeutics has a consensus price target of $4.07, indicating a potential upside of 543.46%. Given CASI Pharmaceuticals' higher possible upside, equities research analysts clearly believe CASI Pharmaceuticals is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, CASI Pharmaceuticals and CASI Pharmaceuticals both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 1.87 beat CASI Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Aprea Therapeutics	Very Positive

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

CASI Pharmaceuticals has a net margin of -183.93% compared to Aprea Therapeutics' net margin of -4,405.59%. CASI Pharmaceuticals' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Summary

Aprea Therapeutics beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Synlogic?

CASI Pharmaceuticals (NASDAQ:CASI) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Synlogic. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Synlogic. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Synlogic	Neutral

Synlogic has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Synlogic	N/A	-26.47%	-18.00%

CASI Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Synlogic has lower revenue, but higher earnings than CASI Pharmaceuticals. Synlogic is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Synlogic	$8K	979.28	-$23.36M	-$0.06	N/A

Summary

CASI Pharmaceuticals beats Synlogic on 9 of the 15 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.55M	$3.07B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-0.07	20.29	27.14	23.64
Price / Sales	0.10	485.19	517.06	88.99
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	1.73	4.13	10.28	6.07
Net Income	-$39.26M	$65.94M	$3.60B	$331.99M
7 Day Performance	N/A	-4.16%	-1.27%	-0.63%
1 Month Performance	N/A	-3.76%	-0.37%	-2.00%
1 Year Performance	-85.98%	9.94%	18.30%	13.62%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	0.9297 of 5 stars	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180	News Coverage
BON Bon Natural Life	0.8723 of 5 stars	$1.17 +0.4%	N/A	-22.0%	$9.43M	$18.67M	N/A	100	Positive News Gap Up
MTEX Mannatech	1.1076 of 5 stars	$4.56 -3.8%	N/A	-44.5%	$9.15M	$108.04M	N/A	250	News Coverage Positive News Gap Down
AEON AEON Biopharma	0.8211 of 5 stars	$0.36 +10.8%	N/A	-69.1%	$9.03M	N/A	1.98	5	High Trading Volume
APRE Aprea Therapeutics	4.1421 of 5 stars	$0.73 +0.9%	$4.07 +458.3%	-67.3%	$8.94M	$290K	N/A	7	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. BON, MTEX, AEON, APRE, and SYBX

How does CASI Pharmaceuticals compare to Bon Natural Life?

Summary

How does CASI Pharmaceuticals compare to Mannatech?

Summary

How does CASI Pharmaceuticals compare to AEON Biopharma?

Summary

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

Summary

How does CASI Pharmaceuticals compare to Synlogic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. BON, MTEX, AEON, APRE, and SYBX

How does CASI Pharmaceuticals compare to Bon Natural Life?

Does the media refer more to BON or CASI?

Do analysts recommend BON or CASI?

Is BON or CASI more profitable?

Which has preferable earnings and valuation, BON or CASI?

Do institutionals and insiders believe in BON or CASI?

Which has more risk & volatility, BON or CASI?

Summary

How does CASI Pharmaceuticals compare to Mannatech?

Which has higher earnings & valuation, CASI or MTEX?

Do analysts rate CASI or MTEX?

Does the media prefer CASI or MTEX?

Is CASI or MTEX more profitable?

Do institutionals & insiders hold more shares of CASI or MTEX?

Which has more risk & volatility, CASI or MTEX?

Summary

How does CASI Pharmaceuticals compare to AEON Biopharma?

Which has more volatility and risk, CASI or AEON?

Is CASI or AEON more profitable?

Do analysts recommend CASI or AEON?

Do institutionals and insiders hold more shares of CASI or AEON?

Does the media prefer CASI or AEON?

Which has higher valuation and earnings, CASI or AEON?

Summary

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

Do institutionals & insiders believe in CASI or APRE?

Which has stronger earnings and valuation, CASI or APRE?

Do analysts recommend CASI or APRE?

Does the media prefer CASI or APRE?

Which has more volatility & risk, CASI or APRE?

Is CASI or APRE more profitable?

Summary

How does CASI Pharmaceuticals compare to Synlogic?

Does the media prefer CASI or SYBX?

Is CASI or SYBX more profitable?

Do analysts prefer CASI or SYBX?

Which has more volatility and risk, CASI or SYBX?

Do insiders & institutionals believe in CASI or SYBX?

Which has better earnings & valuation, CASI or SYBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools